StockTipsArenaBeta

BUY Dr. Reddy's Laboratories Limited — Nirav Chheda, Nirmal Bang Securities

BUYDr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories share price target & all analyst calls

byNirav Chheda, Nirmal Bang SecuritiesHorizon: NA (inferred Swing (≤2wk))29 Sept 2026via CNBC Awaaz.

Entry₹1,240.4Inferred
Target₹1,320
Total upside +6.42% (call closed)
Stop loss₹1,215-2.05% risk
Exit₹1,2151 Oct 2026, 9:20 am
Stop-loss hit-2.05%
Follow Nirav Chheda for new calls(19% target hit, 103 closed calls)Get alertsWatch DRREDDY for new buy/sell callsGet alertsSee 1 active Swing call on DRREDDYSee 282 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 1 Oct 2026
6 supporting2 opposing
Supports the BUY call (6)

Hikma signs exclusive licensing and distribution agreement with Dr. Reddy’s Laboratories for Nicotinell across MENA

NewsGoogle News·28 Sept · 2d ago

(opens in new tab)

4 advisors have active short-term BUY calls on this stock, with 2 issued in the last 14 days

Advisor consensus · adjacent horizon·28 Sept · 2d ago

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·28 Sept · 2d ago

Dr Reddy's Laboratories stock gains as Q1 profit falls

NewsGoogle News·23 Sept · 1w ago

(opens in new tab)

Dr. Reddy's Laboratories has entered into an exclusive distribution and marketing agreement with Takeda Biopharmaceuticals India for Qdenga®, a dengue vaccine, in the private market in India. The agre

BSE · Company Update·18 Sept · 2w ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (2)

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

NewsGoogle News·25 Sept · 6d ago

(opens in new tab)

Dr. Reddy's faces securities fraud probe after Q1 earnings hit by semaglutide batch issues.

NewsGoogle News·24 Sept · 1w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Dr. Reddy's Laboratories

All analyst calls on Dr. Reddy's Laboratories

More from Nirav Chheda, Nirmal Bang Securities

Every call and its outcome